Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4 Menorat Hamaor St. TEL AVIV-YAFO 6744832 |
Tel: | 1-888-7766804 |
Website: | https://www.inspiremd.com/en |
IR: | See website |
Key People | ||
Marvin L. Slosman President, Chief Executive Officer, Director | Craig Shore Chief Financial Officer, Treasurer, Company Secretary | Andrea Tommasoli Chief Operating Officer |
Amir Kohen Vice President - Finance, Human Resources | Shane Gleason Vice President - Global Marketing, General Manager, North America |
Business Overview |
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. |
Financial Overview |
For the fiscal year ended 31 December 2023, InspireMD Inc revenues increased 20% to $6.2M. Net loss increased 8% to $19.9M. Revenues reflect Other segment increase of 14% to $3.4M, Russia segment increase of 94% to $738K. Higher net loss reflects Stock-based Compensation in SGA increase from $1.4M to $3.3M (expense), General and administrative - Balancing v increase of 11% to $7.8M (expense). |
Employees: | 65 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7.30M as of Dec 31, 2023 |
Annual revenue (TTM): | $6.21M as of Dec 31, 2023 |
EBITDA (TTM): | -$20.91M as of Dec 31, 2023 |
Net annual income (TTM): | -$19.92M as of Dec 31, 2023 |
Free cash flow (TTM): | -$16.76M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 23,401,435 as of Apr 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |